Clinical Trial: NCT05840016
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Akeso |
| Information Provided By: | Akeso |
| Last Update Posted: | 2025-05-02 |
Study Overview
Brief Summary
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.
Official Title
Conditions
Intervention / Treatment
- Drug: AK112, Carboplatin, Paxlitaxel
- Drug: Tislelizumab, Carboplatin, Paxlitaxel
Other Study ID Numbers
- AK112-306
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Akeso |
| Information Provided By: | Akeso |
| Last Update Posted: | 2025-05-02 |
Study Overview
Brief Summary
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.
Official Title
Conditions
Intervention / Treatment
- Drug: AK112, Carboplatin, Paxlitaxel
- Drug: Tislelizumab, Carboplatin, Paxlitaxel
Other Study ID Numbers
- AK112-306